MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.22.01824

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023

Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.

Xia Jieyun, Li Hujun, Yan Zhiling, Zhou Dian, Wang Ying, Qi Yuekun, Cao Jiang, Li Depeng, Cheng Hai, Sang Wei, Zhu Feng, Sun Haiying, Chen Wei, Qi Kunming, Yan Dongmei, Qiu Tingting, Qiao Jianlin, Yao Ruosi, Liu Yang, Wang Xue, Zhang Yanlei, Peng Shuixiu, Huang Chih-Hua, Zheng Junnian, Li Zhenyu, Chang Alex H, Xu Kailin

Клиническое исследование II фазыСтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: G protein-coupled receptor, class C group 5 member D (GPRC5D) is considered to be a promising surface target for multiple myeloma (MM) immunotherapy. Here, we report the efficacy and safety of anti-GPRC5D chimeric antigen receptor (CAR) T cells in patients with relapsed or refractory (R/R) MM.

METHODS

This phase Ⅱ, single-arm study enrolled patients (18-70 years) with R/R MM. Lymphodepletion was performed before patients received 2 × 106/kg anti-GPRC5D CAR T cells. The primary end point was the proportion of patients who achieved an overall response. Safety was also evaluated in eligible patients.

RESULTS

From September 1, 2021, to March 23, 2022, 33 patients were infused with anti-GPRC5D CAR T cells. At a median follow-up of 5.2 months (range, 3.2-8.9), the overall response rate was 91% (95% CI, 76 to 98; 30 of 33 patients), including 11 (33%) stringent complete responses, 10 (30%) complete responses, four (12%) very good partial responses, and five (15%) partial responses. Partial responses or better were observed in nine (100%) of nine patients with previous anti-B-cell maturation antigen (BCMA) CAR T-cell therapy, including two patients who had received repeated anti-BCMA CAR T-cell infusions with no responses at the last time. Grade 3 or higher hematologic toxicities were neutropenia (33 [100%]), anemia (17 [52%]), and thrombocytopenia (15 [45%]). Cytokine release syndrome occurred in 25 (76%) of 33 patients (all were grade 1 or 2), and neurotoxicities in three patients (one grade 2 and one grade 3 ICANSs and one grade 3 headache).

CONCLUSION

Anti-GPRC5D CAR T-cell therapy showed an encouraging clinical efficacy and manageable safety profile in patients with R/R MM. For patients with MM that progressed after anti-BCMA CAR T-cell therapy or that is refractory to anti-BCMA CAR T cell, anti-GPRC5D CAR T-cell therapy might be a potential alternative option.

Для цитирования: Xia Jieyun, Li Hujun, Yan Zhiling, Zhou Dian, Wang Ying, Qi Yuekun, Cao Jiang, Li Depeng, Cheng Hai, Sang Wei, Zhu Feng, Sun Haiying, Chen Wei, Qi Kunming, Yan Dongmei, Qiu Tingting, Qiao Jianlin, Yao Ruosi, Liu Yang, Wang Xue, Zhang Yanlei, Peng Shuixiu, Huang Chih-Hua, Zheng Junnian, Li Zhenyu, Chang Alex H, Xu Kailin. Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023. DOI: 10.1200/jco.22.01824.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.